# Additional Screening With Sensitives RDTs and Malaria

> **NCT04147546** · PHASE3 · COMPLETED · sponsor: **Institut de Recherche en Sciences de la Sante, Burkina Faso** · enrollment: 340 (actual)

## Conditions studied

- Plasmodium Falciparum Malaria
- Malaria Diagnosis

## Interventions

- **DIAGNOSTIC_TEST:** Additional screening using ultra sensitive RDTs
- **DRUG:** Dihydroartemisinin-piperaquin
- **OTHER:** Reminders

## Key facts

- **NCT ID:** NCT04147546
- **Lead sponsor:** Institut de Recherche en Sciences de la Sante, Burkina Faso
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-31
- **Primary completion:** 2021-08-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 340 (ACTUAL)
- **Last updated:** 2023-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04147546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04147546, "Additional Screening With Sensitives RDTs and Malaria". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04147546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*